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Abstract
Background The assessment of health-related quality of life (HRQoL) in patients with pemphigus is now of increasing
interest due to the availability of highly effective new therapies. Preference-based HRQoL values or health utilities
required for medical and financial decision-making are not yet available directly from pemphigus patients.
Objective To obtain health utility values for current health and hypothetical health states from the perspective of pem-
phigus patients.
Methods A cross-sectional questionnaire survey was carried out with pemphigus patients. Disease severity was rated
by Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). Patients were asked to evaluate their current health as
well as three common hypothetical pemphigus health states [uncontrolled pemphigus vulgaris (PV), uncontrolled pem-
phigus foliaceus (PF) and controlled PV/PF] by using composite time trade-off (cTTO). Multiple regression was applied to
explore determinants of utility values.
Results Responses of 108 patients (64.8% women, mean age 57.4 years) were analysed. Mean ABSIS score was
11.6. The mean utility values for the hypothetical uncontrolled PV, uncontrolled PF and controlled PV/PF health states
were 0.41, 0.52 and 0.66 with cTTO. The mean cTTO scores for current health were higher compared with the hypotheti-
cal health states (0.76; P < 0.001). Patients with higher ABSIS, worse pain intensity scores and those having a caregiver
reported lower utility values for current health (P < 0.05).
Conclusions In pemphigus, HRQoL impairment expressed in utility values seems to be considerable, especially in
comparison with other chronic dermatological conditions (e.g. psoriasis, atopic eczema, chronic hand eczema). These
health utilities inform physicians, policymakers and funders about the overall extent of health loss in pemphigus and pro-
vide evidence to guide medical decisions and cost-effectiveness analyses of treatment strategies. Future research is
needed to evaluate the caregiver burden in pemphigus.
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Introduction
Pemphigus is a group of rare chronic autoimmune diseases of
the skin and mucosa.1,2 Reported incidence varies between 0.5
and 32 per million across geographic regions.3 Typical age of
onset is 50–60 years, and it is more common in women.4 There
are two major subtypes of disease: pemphigus vulgaris (PV) and
pemphigus foliaceus (PF). Clinical manifestation of PV includes
the formation of painful flaccid blisters on the skin and/or
mucosa, commonly in the oral cavity.5 PF is characterized by
crusted erosions on the skin, while oral lesions are rarely seen in
this form of disease.5 Skin lesions can develop on any body part;
however, they generally appear on the scalp, upper chest and
back.
Health-related quality of life (HRQoL) in pemphigus is now
of increasing interest due to the US Food and Drug Administra-
tion (FDA) approval of the first-line application of a biologic
agent, rituximab for PV in June 2018.6 Autoimmune blistering
diseases including pemphigus are reported to cause one of the
largest HRQoL impairment among chronic skin diseases.7–9
HRQoL outcomes are increasingly being recognized as an
important tool to aid treatment decisions in dermatology.10–12 A
method to quantify the HRQoL loss from disease and the
HRQoL benefits of treatments is the assessment of health utility
values. So far, many HRQoL studies have been performed with
pemphigus patients;13,14 however, none of these elicited health
utility values. Health utilities represent preferences for a given
health state measured on a cardinal scale anchored on 0 (=death)
and 1 (=full health). In addition to assessing the burden of dis-
ease, utilities may be used to calculate quality-adjusted life years
(QALYs). The QALY is a single index that combines the impact
of health interventions on both mortality (i.e. survival) and
morbidity (i.e. utility gain).15 One year spent in ‘full health’
equals 1 QALY. For instance, when a treatment results in
10 years of survival and an average utility improvement of 0.2
that yields a total of two QALYs gained. In cost-effectiveness
analyses, estimating the cost of a QALY gained is a useful out-
come to compare the benefits of two alternative treatment
strategies.16
Undoubtedly, the rarity of disease represents a major limita-
tion of assessing health utilities in pemphigus. Few patients char-
acterized by severe skin lesions are accessible, as the majority of
patients are treated and presenting with milder symptoms in sec-
ondary or tertiary care settings. Our main aim was to elicit
health utility values directly from pemphigus patients. Thus,
patients in this study valued both their current health and three
common hypothetical pemphigus health states (uncontrolled
PV, uncontrolled PF and controlled PV/PF) based on vignettes
describing symptoms and HRQoL impact of disease. The issue
of whose preferences to elicit for economic evaluations is widely
discussed in the literature.17,18 In most European countries, util-
ities obtained from the general public are recommended; never-
theless, health valuations typically differ between patients and
the general population. The secondary aim was to compare utili-
ties for these three states derived from patients and the general
population.19
Methods
Study setting and patients
Between December 2014 and June 2017, a cross-sectional ques-
tionnaire survey was carried out. Consecutive pemphigus
patients (≥18 years of age) regardless of type and severity of
pemphigus were recruited to the study at all four university der-
matology clinics in Hungary. All patients agreed to take part in
the survey and signed in an informed consent. Ethical approval
was obtained from the National Scientific and Ethical Commit-
tee (reference no. ETT-TUKEB 27416-3/2016/EKU). Outpatients
filled in the questionnaires right after clinical examinations at
the doctor’s office or in the waiting room, while hospitalized
patients completed the survey in the ward. Patients answered
questions on personal data (e.g. age, gender, education) and
pain experienced. The average and worst pemphigus-related
pain intensity in the past three months was recorded on a hori-
zontal visual analogue scale (VAS) with the endpoints of ‘no
pain at all’ (=0) and ‘pain as bad as it could be’ (=10).20
Dermatologists provided data on medical history and treat-
ments as well as rated disease severity by Autoimmune Bul-
lous Skin Disorder Intensity Score (ABSIS). The ABSIS is a
validated scoring system for disease severity in autoimmune
bullous skin diseases, including pemphigus.21,22 ABSIS scores
range between 0 and 206, where higher scores refer to more
severe disease. Out of 206, 150 points can be attached to skin
involvement, 11 points to oral involvement and 45 points to
subjective discomfort.
Dermatology-specific HRQoL was assessed by completing the
Dermatology Life Quality Index (DLQI).23 The DLQI is a self-
administered 10-item questionnaire designed to measure the
impact of skin disease on patients’ life over the past week.
Responses range from ‘not at all’ or ‘not relevant’ (=0), ‘a little’
(=1), ‘a lot’ (=2) to ‘very much’ (=3). The total score is calcu-
lated by adding up the scores of each item, where ‘0’ reflects the
best, and ‘30’ reflects the worst HRQoL.
Utility assessment
The study design builds on an earlier study assessing three pem-
phigus health states by the general population in Hungary.19
Utilities were obtained via paper-based questionnaires, com-
pleted in the presence of a dermatologist who explained the
exercises. Patients filled in the questionnaires themselves, but
they were encouraged to ask any questions either before or dur-
ing the task any time having concerns. The detailed methodol-
ogy of the utility assessment has been published elsewhere,19 and
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we briefly summarize the main points here. An example valua-
tion task is provided in Appendix S1.
Based on results of a systematic literature review13 on HRQoL
in pemphigus, three health state descriptions – an uncontrolled
PV, an uncontrolled PF and a controlled PV/PF – were defined
reflecting different pemphigus experiences according to skin and
mucosal symptoms, possible food avoidance, bathing and/or
clothing issues, and effects on work and social life
(Appendix S2). According to the European S2 guideline for
diagnosis and treatment of pemphigus, control of disease activity
was defined by the time at which new lesions cease to form and
established lesions begin to heal.24 In order to determine the
clarity of descriptions, the health state vignettes were pilot-tested
in four pemphigus patients. The vignettes were presented in a
table format, as patients strongly prefer this format over narra-
tive health state descriptions.25
Composite time trade-off (cTTO) was used for the health
state valuations. The cTTO task combines a conventional TTO
to elicit values for states regarded better than dead and a lead-
time TTO for states worse than dead.26 In the conventional TTO
for current health, patients were asked to imagine that they were
living in their current health status for the next 10 years fol-
lowed by death. Then, they were asked to find the amount of
time in full health, which is considered equal to 10 years in their
current health (Appendix S1, Q1). The lead-time TTO was
introduced for those patients who chose immediate death over
10 years in their own health. These respondents were given 10
extra years in full health before the 10 years to live in pemphigus
(a total of 20 years), while the alternative option offered a
shorter life span (i.e. a maximum of 10 years) in full health
(Appendix S1, Q2).26 A similar procedure was followed for the
three hypothetical states.
Data analysis
Invalid or logically inconsistent cTTO responses were excluded.
A response sheet was considered invalid (i) if the patient did not
complete each row of the cTTO sheet, but only indicated a
response at a single year; (ii) if the patient indicated a ‘cannot
decide’ answer at each year; and (iii) if an answering pattern was
detected [i.e. the patient provided exactly the same response pat-
tern for each cTTO task), with the exception of non-trading
behaviour (i.e. rated all health states including current health
equal to full health)]. Examples for inconsistent cTTO response
sheets are published elsewhere.27
cTTO responses were scored by two researchers with experi-
ence in using the method conforming to the guidelines described
by Gudex et al.28 Utility values were calculated according to the
following formulas, with utilities anchored on 0 (death) and 1
(full health):
Better than dead responses:U ¼ t
10
Worse than dead responses:U ¼ t  10
10
;
where U is the utility value, and t is the number of years required
in full health.26 For example, if a patient is indifferent between
10 years in pemphigus and 6 years in full health, the utility is
calculated as U = 6/10 = 0.6. For states worse than dead, if a
patient considers 10 years in full health followed by 10 years in
pemphigus to be equal to 2 years in full health, U = (2–10)/
10 = 0.8.
Descriptive statistics (mean, median, standard deviation,
IQR) of utility values were computed. A Wilcoxon signed-rank
test was used to test the difference in cTTO utilities between
health states. We assessed the association between cTTO utilities
for current health and DLQI and ABSIS scores by Spearman’s
correlation coefficients. We performed multiple generalized least
squares (GLS) regression analyses to explore demographic and
clinical predictors of utilities. We adopted a repeated measures
approach, whereby observations were grouped within individu-
als. We used a mixed model assuming fixed effects both for the
hypothetical health states and for the observed individual char-
acteristics, complemented by a random intercept for each indi-
vidual plus an idiosyncratic error term.
For each health state, utility values derived from patients were
compared to results of an earlier study eliciting utilities for
exactly the same three health states from a convenience sample
of the general population in Hungary.19 Given the differences in
demographic and socioeconomic characteristics between
patients and the general public, we adjusted utility values for
participants’ age, gender, education level and employment sta-
tus. Analysis of covariance (ANCOVA) was applied to compute
adjusted mean utility values for hypothetical health states of the
two groups. All statistics were two-sided, and a P < 0.05 was
taken as statistically significant. All analyses were undertaken in
IBM SPSS (version 22.0, IBM Corp., Armonk, NY, USA) and R
(version 3.5.0, R Core Team, Vienna, Austria).
Results
Characteristics of the patient population
Overall, 108 patients participated in the survey. Demographic
and clinical characteristics of the patients are presented in
Table 1. Mean  SD age was 57.4  14.7 years, and 64.8%
were women. With respect to disease severity, the majority of
patients were in a relatively mild health state (mean ABSIS score
11.6  17.4 on a scale from 0 to 206). Mean DLQI score of
patients with pemphigus was 5.5  6.9 (on a scale from 0 to 30).
Utility results
Figure 1 shows that overall five cTTO tasks were left blank from
three patients. A further 71 (16.3%) cTTO tasks were excluded
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according to the exclusion criteria. The most common reason
for exclusion was indicating the ‘cannot decide’ response option
for each year (8.7%).
The rate of ‘1’ answers (i.e. full health) on the cTTO was
14.0% for uncontrolled PV, 19.3% for uncontrolled PF,
34.1% for controlled PV/PF and 54.6% for current health.
There were eight patients (7.4%) who were non-traders (i.e.
rated all health states including their current health equal to
‘1’; Table 2). Overall 11.6%, 9.0% and 3.3% judged the
uncontrolled PV, uncontrolled PF and controlled PV/PF
health states as bad or worse than being dead (utility ≤ 0).
In contrast, there was only one ‘0’ utility, and no negative
utilities occurred for current health.
Table 2 shows that mean  SD utility values for the hypo-
thetical uncontrolled PV, uncontrolled PF and controlled PV/PF
health states were 0.41  0.45, 0.52  0.42 and 0.66  0.36.
Significant differences were observed between all hypothetical
health states (P < 0.001). The mean cTTO scores for current
health were higher compared with the hypothetical health states
(0.76  0.30; P < 0.001). There was no significant difference
between PV and PF patients (0.75  0.30 vs. 0.78  0.30,
P = 0.771). cTTO scores for current health demonstrated a weak
correlation with DLQI (r = 0.29, P = 0.006) and a very weak
correlation with ABSIS scores (r = 0.14, P = 0.200).
Predictors of utilities
Table 3 presents the results of multiple regression analyses about
predictors of cTTO utilities. The uncontrolled PV and uncon-
trolled PF health states implied a 0.306 and 0.156 lower mean
cTTO values in comparison with the controlled PV/PF health
state. Patients’ cTTO utilities for hypothetical health states were
decreased by 0.0070 with every one-year increase in age. ABSIS
had a positive, although diminishing effect on cTTO values, as is
implied by the negative coefficient of the quadratic term
(ABSIS2).
With respect to current health, patients who assigned one unit
higher cTTO rating for the hypothetical controlled PV/PF health
state also tended to evaluate their current health 0.555 units
higher on average. Every point increase on worst pain as mea-
sured with the VAS pain scale decreased the cTTO utility for
current health state by 0.017, and furthermore, patients reported
to have a caregiver provided on average 0.131 lower cTTO val-
ues. We have also found a diminishing negative effect for ABSIS
on cTTO utilities.
Comparison of utilities between patients and the general
public
Mean differences between the utility values for the three hypo-
thetical health states from patients vs. the general population are
presented in Table 2. A convenience sample of the general popu-
lation was recruited in 2015.19 They had a mean age of
26.0  9.1 years, 58% were females, 78% had a college/univer-
sity degree, and 51% was employed. No significant differences
were found in cTTO utilities for hypothetical health states,
which remained unchanged after adjusting for demographic and
socioeconomic characteristics (mean adjusted cTTO utilities for
uncontrolled PV, uncontrolled PF and controlled PV/PF were
0.43, 0.55 and 0.68; P > 0.05 for all).
Discussion
This study aimed to obtain health utility values for current
health and hypothetical health states from the perspective of
pemphigus patients. As a practical matter, current health utilities
are useful for understanding the HRQoL burden pemphigus
poses on HRQoL of patients, while the utilities for hypothetical
health states may be applied for estimating QALYs in economic
evaluations of pemphigus treatments.
Table 1 Characteristics of the patient population (n = 108)
Variables Mean (SD) or
N (%)
Age (years) 57.4 (14.7)
Gender
Female 70 (64.8%)
Male 38 (35.2%)
Education
Primary school 22 (20.4%)
High school 57 (52.8%)
College/university 29 (26.9%)
Employment status†
Employed 51 (47.2%)
Unemployed 6 (5.6%)
Disability pensioner 14 (13.0%)
Retired 38 (35.2%)
Student 1 (0.9%)
Other 4 (3.7%)
Having a caregiver 28 (25.7%)
Disease duration (years) 3.8 (4.9)
Type of pemphigus
Pemphigus vulgaris 80 (74.1%)
Pemphigus foliaceus 27 (25.0%)
IgA pemphigus 1 (0.9%)
Outcome measures‡
ABSIS (0–206) 11.6 (17.4)
DLQI (0–30) (missing n = 1) 5.5 (6.9)
Average pain intensity VAS§ (0–10) (missing n = 3) 2.14 (3.1)
Worst pain intensity VAS§ (0–10) (missing n = 2) 3.4 (3.8)
Current treatment
None 3 (2.8%)
Topical therapy (only) 10 (9.3%)
Systemic therapy 95 (88.0%)
†Combinations may occur.
‡For all outcome measures, a higher score represents a worse outcome.
§For the past 3 months.
ABSIS, Autoimmune Bullous Skin Disorder Intensity Score; VAS visual ana-
logue scale.
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Mean cTTO utility for patients’ current health was 0.76 on
a scale anchored on 0 (=death) and 1 (=full health). To put
this in another way, patients were willing to trade 24% of
their remaining hypothetical 10-year life expectancy to be free
from pemphigus. The relatively low utility values in pemphi-
gus compared to other skin diseases reflect the large impact
of PV and PF on the life of these patients.29–37 In other stud-
ies, patients with various chronic dermatological conditions
valued their actual health as follows (mean values):
hidradenitis suppurativa 0.63,31 systemic sclerosis 0.76,33,34
psoriasis 0.88,32 melasma 0.92,35 atopic dermatitis 0.93,32 port
wine stains 0.9536 and acne 0.96.37 However, results of these
studies are not directly comparable to those of our study due
to differences in the TTO methodologies, such as varying
length of time frame in the TTO task.
In our study, cTTO utilities for current health demonstrated a
weak correlation with disease severity. Previously, a large num-
ber of studies in various diseases found no or at most modest
correlation between disease severity measures and health utili-
ties.38 Examples from the field of dermatology include Melasma
Area Severity Index, Investigator’s Static Global Assessment
score in acne and Hurley staging in hidradenitis suppura-
tiva.31,35,37 Evidence suggests that clinical variables may explain
only a part of health utilities, while person-related variables such
as socioeconomic status, having children and attitudes towards
death represent the major source of variation.39
Total cTTO responses 
(n = 432) 
from N = 108 patients
Missing (n = 5)
• Current health (n = 1), 
• Uncontrolled PV (n = 1), 
• Uncontrolled PF (n = 1), 
• Controlled pemphigus (n = 2) 
Total completed cTTO responses 
(n = 427)
Excluded (n = 71)
Invalid responses* (n = 58):
• Only one row is completed on the task sheet (n = 12) 
• ‘Cannot decide’ response given at each year (n = 38) 
• Response patterns in all health states** (n = 36)
Inconsistent responses (n = 13):
• The point of indifference occurs after the respondent has stopped trading 
and refused further trading (n = 5)
• The point of indifference is followed by trading life years (n = 8)
Total valid cTTO responses
for analysis 
(n = 356 from N = 108 patients)
• Current health (n = 90), 
• Uncontrolled PV (n = 86), 
• Uncontrolled PF (n = 89), 
• Controlled pemphigus (n = 91)
Figure 1 Study flow diagram. *A single response might be invalid due to more than one reason. **The patient provided exactly the same
response pattern for each cTTO with the exception of non-trading behaviour, when following a pattern is acceptable. cTTO, composite
time trade-off; PF, pemphigus foliaceus; PV, pemphigus vulgaris.
Table 2 cTTO utilities for current health and hypothetical pemphigus health states
Pemphigus patients (n = 108) General population (n = 108)19 Mean difference P-value
n Mean (SD) Median n Mean (SD) Median
Current health 90 0.76 (0.30) 0.90 N/A N/A N/A N/A N/A
Uncontrolled PV 86 0.41 (0.45) 0.40 104 0.35 (0.38) 0.40 0.07 0.278
Uncontrolled PF 89 0.52 (0.42) 0.50 106 0.52 (0.32) 0.50 0.00 0.974
Controlled PV/PF 91 0.66 (0.36) 0.80 107 0.75 (0.31) 0.80 0.09 0.056
Source of data on general population values: Rencz et al.19
cTTO, composite time trade-off; N/A, not applicable; PF, pemphigus foliaceus; PV, pemphigus vulgaris.
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Our results are in accordance with earlier studies assessing
HRQoL and its predictors in patients with pemphigus by using
EQ-5D, SF-36, WHOQOL-BREF, DLQI and Skindex-29.14,40–47
Moreover, having a caregiver was associated with lower utilities
for current health. Pemphigus may not only adversely affect
HRQoL of patients but also places a burden on caregivers. The
European Academy of Dermatology and Venereology (EADV)
quality of life task force advocates that the impact of a skin dis-
ease on family and caregivers should be measured as part of any
thorough evaluation of the burden of a disease.48
Regarding the hypothetical health states, the mean cTTO util-
ities were 0.41 for uncontrolled PV, 0.52 for uncontrolled PF
and 0.66 for controlled PV/PF. Utilities may be obtained from
patients or the general population. Our results show that in case
of the three hypothetical pemphigus health states, preferences of
patients and the general public are not significantly different.
This is in line with results of a meta-analysis of 22 TTO studies
by Peeters et al.49 who reported that when patients rated hypo-
thetical health state descriptions, their values were, in fact, very
similar to those obtained from non-patients (P > 0.05).
Utility values from our study can be used to estimate QALYs
in cost-effectiveness models. The large differences in utilities
between the uncontrolled and controlled health states suggest
that the successful treatment of pemphigus may generate a sig-
nificant QALY gain. In many countries including the United
States, Canada and most European countries, health technology
assessment (HTA) bodies require cost/QALY estimates for every
new medication seeking reimbursement.50–55 High-quality and
timely evidence on cost-effectiveness may make a substantial
impact on speeding up access to innovative medicines for
patients in need.
A strength is that this study is the first to elicit health utility
values directly from patients with pemphigus. Other strengths
include the relatively large sample size in comparison with previ-
ous HRQoL studies in pemphigus,13 especially in light of the rar-
ity of the condition. The patient population was heterogeneous
with regard to demographic as well as clinical characteristics,
which satisfies the purpose of this valuation study. Our study
had some limitations. First, patients were mostly well-controlled
and just a few patients with severe symptoms entered the study.
Secondly, disease activity was measured by only one instrument
(ABSIS). Compared to the ABSIS, Pemphigus Disease Area
Index indicated somewhat better measurement properties in
patients with mild disease activity.22 Thirdly, a total of 17.6% of
cTTO responses were invalid or inconsistent which suggests that
the cTTO task is challenging, despite supervision by a dermatol-
ogist.
In conclusion, our findings inform physicians, policymakers
and funders about the overall extent of health loss in pemphigus.
Health utilities for current and hypothetical health states con-
firmed that pemphigus is associated with a detrimental impact
on patients’ HRQoL. Given the recent availability of highly
Table 3 Predictors of cTTO utility values (multiple linear regressions)
Coeff. (b) SE P-value
cTTO hypothetical
Intercept 0.982 0.108 <0.001
Hypothetical pemphigus health states
Uncontrolled PV 0.306 0.054 <0.001
Uncontrolled PF 0.156 0.043 <0.001
Clinical and demographic characteristics of patients
Age 0.0070 0.0018 <0.001
ABSIS 0.0088 0.0032 0.006
ABSIS2 0.00016 0.00004 <0.001
cTTO current health
Intercept 0.486 0.058 <0.001
Hypothetical controlled PV/PF health state cTTO utility 0.555 0.079 <0.001
Clinical and demographic characteristics of patients
Having a caregiver 0.131 0.065 0.042
Worst pain intensity VAS 0.017 0.008 0.038
ABSIS 0.0080 0.0035 0.023
ABSIS2 0.00016 0.00004 <0.001
Unrestricted generalized least squares (GLS) estimates. R-squared: 0.387 for current health VAS, 0.244 for hypothetical cTTO and 0.492 for current health
cTTO. Independent variables: ABSIS: score on Autoimmune Bullous Skin Disorder Intensity Score (0–206); Age = patient’s age (years); Having a caregiver:
no = 0; yes = 1; Hypothetical controlled PV/PF health state cTTO utility: cTTO utility for the hypothetical controlled PV/PF health state on a 1 to 1 scale;
Hypothetical uncontrolled PF health state: no = 0, yes = 1; Hypothetical uncontrolled PV health state: no = 0, yes = 1;Worst pain intensity VAS: worst pain
experienced in the past 3 months on a 0–10 visual analogue scale.
ABSIS, Autoimmune Bullous Skin Disorder Intensity Score; cTTO, composite time trade-off; PF, pemphigus foliaceus; PV, pemphigus vulgaris; VAS, visual
analogue scale.
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effective therapy such as first-line rituximab, the assessment of
pemphigus-related outcomes based on treatment is essential.
Utility values from this study allow to quantify the burden of
pemphigus in a way that is compatible with the medical and
financial decision-making processes.
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